Non-enzymatic role of dipeptidyl peptidase-4 in regulating adenosine 2A receptor in MAFLD
Journal of Endocrinology · 01.11.2026 · 271 (2)
DOI: 10.1530/joe-26-0029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, online erschienen am 22.10.2026. Verfasst von Yuli Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Renmin Hospital of Wuhan University , Wuhan, China. Hauptthemen laut MEDLINE: Dipeptidyl Peptidase 4, Receptor, Adenosine A2A, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The non-catalytic function of dipeptidyl peptidase-4 (DPP4) plays a crucial role in inflammation and immune regulation in the body; however, its significance in metabolic-associated fatty liver disease (MAFLD) remains largely unknown. We sought to examine the effects of Dpp4 disruption on aspects of MAFLD and elucidate the underlying mechanisms. Wild-type (WT), Dpp4-disrupted, and DPP4 inhibitor-treated C57BL/6J male mice were fed a high-fat diet (HFD) for 12 weeks to establish MAFLD. Hepatic steatosis and liver proinflammatory responses were assessed. Furthermore, bone marrow-derived macrophages from different genotypes were co-cultured with mouse hepatocytes to assess their roles in inflammatory and metabolic responses in vitro. Upon HFD feeding, Dpp4-disrupted mice exhibited significantly attenuated hepatic steatosis and inflammation compared with both DPP4 inhibitor-treated and control WT mice. In vitro, Dpp4-deficient macrophages demonstrated a reduced proinflammatory phenotype. Consequently, these macrophages elicited less fat deposition in co-cultured wild-type hepatocytes. Mechanistically, Dpp4 deficiency significantly upregulated the protein abundance of the adenosine 2A receptor (A2AR) while markedly reducing adenosine deaminase (ADA) levels in both liver tissues and bone marrow-derived macrophages. Our results demonstrate that genetic disruption of Dpp4, unlike its pharmacological inhibition, ameliorates MAFLD progression. This protective effect is mediated through a novel non-catalytic mechanism involving the upregulation of A2AR and downregulation of ADA, which collectively inhibit macrophage-driven inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Renmin Hospital of Wuhan University , Wuhan, China.
- Department of Neurology, Renmin Hospital of Wuhan University , Wuhan, China.
- Department of Geriatrics, Renmin Hospital of Wuhan University , Wuhan, China.
- Department of Anesthesiology, Renmin Hospital of Wuhan University , Wuhan, China.
ORCID-Profile: Yuli Cai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cai, Y., Niu, X., Wang, Y., Liu, W., Li, Q., Ma, J., Chen, X., Li, J., Yi, B., & Wen, Z. (2026). Non-enzymatic role of dipeptidyl peptidase-4 in regulating adenosine 2A receptor in MAFLD. Journal of Endocrinology, 271(2). https://doi.org/10.1530/joe-26-0029
Vancouver
Cai Y, Niu X, Wang Y, Liu W, Li Q, Ma J, et al. Non-enzymatic role of dipeptidyl peptidase-4 in regulating adenosine 2A receptor in MAFLD. Journal of Endocrinology. 2026;271(2). doi:10.1530/joe-26-0029
BibTeX
@article{Cai2026,
author = {Cai, Yuli and Niu, Xuan and Wang, Ye and Liu, Wei and Li, Qingwen and Ma, Jingjing and Chen, Xiaolin and Li, Junfeng and Yi, Bo and Wen, Zhongyuan},
title = {Non-enzymatic role of dipeptidyl peptidase-4 in regulating adenosine 2A receptor in MAFLD},
journal = {Journal of Endocrinology},
year = {2026},
volume = {271},
number = {2},
doi = {10.1530/joe-26-0029}
}
EUVIMED